RajivAgarwal United States

Upload Picture

First Name

Rajiv

Last Name

Agarwal

Institution

Country.

United States

Time	Session

2:15 p.m. 3:45 p.m.	HIT! High Impact Clinical Trials – What and Why HIT1 AndreaViecelli Chair AustraliaUniversity of Queensland VivekKumar Chair IndiaPostgraduate Institute of Medical Education and Research, Chandigarh, India Combination Effect of Finerenone and Empagliflozin in Participants With Chronic Kidney Disease and Type 2 Diabetes Using a UACR Endpoint Study (CONFIDENCE) HIT1-1 RajivAgarwal Oral Abstract Presenter United States Results From the REGENCY Trial Assessing Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis HIT1-2 BradRovin Oral Abstract Presenter United StatesThe Ohio State University Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial HIT1-3 KatherineTuttle Oral Abstract Presenter United StatesUniversity of Washington School of Medicine, Division of Nephrology Brahmkamal Hall - Plenary Hall

Time

Session

2:15 p.m.

3:45 p.m.

HIT! High Impact Clinical Trials – What and Why

AndreaViecelli Chair AustraliaUniversity of Queensland

VivekKumar Chair IndiaPostgraduate Institute of Medical Education and Research, Chandigarh, India

Combination Effect of Finerenone and Empagliflozin in Participants With Chronic Kidney Disease and Type 2 Diabetes Using a UACR Endpoint Study (CONFIDENCE)

HIT1-1

RajivAgarwal Oral Abstract Presenter United States
Results From the REGENCY Trial Assessing Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis

HIT1-2

BradRovin Oral Abstract Presenter United StatesThe Ohio State University
Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial

HIT1-3

KatherineTuttle Oral Abstract Presenter United StatesUniversity of Washington School of Medicine, Division of Nephrology

Brahmkamal Hall - Plenary Hall